Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNYZ) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Ligand Pharmaceuticals (LGNYZ) over the last 12 years, with Q3 2025 value amounting to $0.47.

  • Ligand Pharmaceuticals' Debt to Equity changed N/A to $0.47 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.47, marking a year-over-year change of. This contributed to the annual value of $0.13 for FY2022, which is N/A changed from last year.
  • Ligand Pharmaceuticals' Debt to Equity amounted to $0.47 in Q3 2025.
  • Ligand Pharmaceuticals' 5-year Debt to Equity high stood at $0.47 for Q3 2025, and its period low was $0.09 during Q3 2022.
  • In the last 3 years, Ligand Pharmaceuticals' Debt to Equity had a median value of $0.13 in 2022 and averaged $0.19.